Novartis releases new data on benefits of Kesimpta in relapsing multiple sclerosis EP News Bureau Sep 24, 2025 Novartis has released new data from two Kesimpta (ofatumumab) studies in relapsing multiple sclerosis (RMS) that will be presented…
Multiple sclerosis market to generate sales of $29.8 bn by 2030: GlobalData EP News Bureau Apr 19, 2023 Tolebrutinib is expected to be the leading BTK inhibitor by 2030, with forecasted sales of approximately $2.6B across the 7MM
US FDA approves Novartis Kesimpta (ofatumumab) for relapsing forms of MS treatment EP News Bureau Aug 21, 2020 Ofatumumab was first approved by the FDA in 2009 for the treatment of chronic lymphocytic leukaemia (CLL)
